Scalper1 News
Small medical-device firm Abiomed (ABMD) vaulted to a new high Wednesday after the heart pump maker soundly beat expectations and got a new product approval late Tuesday. Sales for its fiscal Q3 ended Dec. 31 rose 34% over the year-earlier quarter to $62 million, some $9 million more than analysts expected, according to Thomson Reuters. Earnings soared 173% to 30 cents a share, pounding the consensus estimate of 4 cents. Abiomed’s guidance for its Scalper1 News
Scalper1 News